ライフサイエンスコーパス: AST

1 AST and ALT elevations are more frequent in US patients

2 AST highly correlated with ALT throughout the illness co

3 AST-dominant aminotransferase elevation is common in COV

4 minotransferase (42 versus 28U/L, P = 0.02), AST (35 versus 25U/L, P = 0.02), AST-to-platelet ratio i

5 P = 0.02), AST (35 versus 25U/L, P = 0.02), AST-to-platelet ratio index (0.77 versus 0.25, P = 0.000

6 ay/week implementation of the direct Vitek 2 AST method from positive blood culture broth for GNR bac

7 The performances of Vitek 2 AST-GN69 and AST-XN06 cards were compared to Clinical an

8 ients had grade 3 rashes and one had grade 3 AST elevation.

9 elevated ALT (HR, 4.08; 95% CI: 1.99-8.33), AST (HR, 4.33; 95% CI: 2.18-8.59), and GGT (HR, 7.91; 95

10 atio index (APRI), fibrosis-4 index (FIB-4), AST/alanine aminotransferase (ALT) ratio (AAR), and age-

11 We analyzed data on 5103 AST results from 10 hospitals.

12 ernational normalized ratio (INR), and day-7 AST were independently associated with PNF on multivaria

13 beta-lactams (termed nuclease-accessibility AST [nuc-aAST]).

14 ults to develop the polymerase-accessibility AST (pol-aAST), a new phenotypic approach for beta-lacta

15 rsR [NGO1562] and rpsO) can deliver accurate AST results across 14 tested isolates.

16 Admission AST (69 vs. 49; P < 0.05), peak AST (364 vs. 77; P = 0.0

17 d patients with COVID-19, both at admission (AST 66.9%, ALT 41.6%, ALP 13.5%, and TBIL 4.3%) and peak

18 paring the hepatic parameters ALP, GGT, ALT, AST and total bilirubin, also considering the adverse ev

19 nd albumin concentrations) and hepatic (ALT, AST) parameters.

20 <6 months by >/=1 additional NAT(s), or ALT, AST, and platelets <90 days, or any test ordered by an i

21 liver inflammation, and decreased serum ALT/AST levels.

22 e aminotransferase/alanine aminotransferase (AST/ALT).

23 elevated plasma aspartate aminotransferase (AST) and 35% had elevated alanine aminotransferase (ALT)

24 Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) decreased signif

25 ansferase (ALT), aspartate aminotransferase (AST) and fetuin-A were determined in fasting blood sampl

26 t an increase in aspartate aminotransferase (AST) and its dynamicity correlated with COVID-19-related

27 ics curve showed aspartate aminotransferase (AST) had highest area under the curve 0.761 (95% CI: 0.6

28 count, elevated aspartate aminotransferase (AST) level, positivity in the nonstructural protein 1 (N

29 ransferase (ALT)/aspartate aminotransferase (AST) levels and less hepatic inflammation when compared

30 antly lower peak aspartate aminotransferase (AST) levels than those receiving CS grafts.

31 fevers, grade 4 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation with fe

32 erase (ALT), and aspartate aminotransferase (AST) using a general linear model for repeated measureme

33 , abnormal serum aspartate aminotransferase (AST) value, Hepatitis C virus (HCV) infection, alcohol a

34 Median aspartate aminotransferase (AST) was higher than alanine aminotransferase (ALT) at a

35 a, patients with aspartate aminotransferase (AST)>100 IU/L and 50 IU/L showed significantly higher va

36 Peak values of aspartate aminotransferase (AST), alanine aminotransferase, lactate dehydrogenase, a

37 blood levels of aspartate aminotransferase (AST), alanine transaminase (ALT), and mitochondrial aspa

38 ansferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamytransf

39 ansferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, creatinine, and improved liv

40 erase (ALT), and aspartate aminotransferase (AST), among a discovery set of 731 participants of the R

41 ansferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) at 52 weeks,

42 ansferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) elevation was

43 t albumin, day-1 aspartate aminotransferase (AST), day-1 lactate, day-3 bilirubin, day-3 internationa

44 ansferase (ALT), aspartate aminotransferase (AST), glucose, total cholesterol, cholesterol high-densi

45 ULN), platelets, aspartate aminotransferase (AST), hemoglobin, sodium, patient age, and number of yea

46 zyme activity of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (C

47 ansferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and thiobarbituric ac

48 e performance of aspartate aminotransferase (AST)-platelet ratio index (APRI) and alpha fetoprotein (

49 Aspartate aminotransferase (AST)-to-platelet ratio (APRI) was calculated as = 100*(a

50 stic accuracy of aspartate aminotransferase (AST)-to-platelet ratio index (APRI), fibrosis-4 index (F

51 27, P = 0.005), aspartate aminotransferase (AST; 26 versus 21, P = 0.01), direct bilirubin (0.13 ver

52 inotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), alkaline phosp

53 cs, liver tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphata

54 ulated as = 100*(aspartate aminotransferase [AST]/upper limit of AST)/platelet.

55 In multivariate analysis, AST within 7 days of initial positive MSSA culture was a

56 o ID (median, 23 vs 2.2 hours, P < .001) and AST (median, 23 vs 7.4 hours, P < .001), from Gram stain

57 significant increases in ALT (p < 0.001) and AST (p = 0.013) with increased fat content and evidence

58 mbin time (14.4 versus 12.4, P = 0.002), and AST-to-platelet ratio index (0.31 versus 0.23, P = 0.003

59 taining and little increase in serum ALT and AST after treatment with JQ1 loaded ApoE-NPs.

60 The mean ALT and AST normalized rapidly between pre-DAA and DAA, whereas

61 294 and 292; and 366 and 321 U/L for ALT and AST, in Vit D, LE and LE + Vit D treated groups, respect

62 manifested by a marked decrease in ALT, and AST serum levels (from 900 and 1021 U/L in the control g

63 s were observed for TG, HbA1c, CRP, ALT, and AST.

64 receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 patients receiving tenofovir alafena

65 The performances of Vitek 2 AST-GN69 and AST-XN06 cards were compared to Clinical and Laboratory

66 mproved overall TAT to ID (18 to 16.5 h) and AST (42.3 to 40.7 h) results compared to MALDI (P < 0.00

67 of ADX significantly reduced time to ID and AST as well as time to optimal antimicrobial therapy but

68 potential to greatly accelerate both ID and AST to inform treatment.

69 .7 h) and 60.5 h (46.6 to 72.4 h) for ID and AST, respectively.

70 ing M30 (rho = 0.375, p = 0.001), as well as AST and ALT (rho = 0.43, p = 0.0004, and rho = 0.27, p =

71 rum markers of liver damage, high aspartate (AST, >49.9 IU/L) and alanine aminotransferase (ALT, >56.

72 three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and dec

73 internal validation for aztreonam-avibactam AST by reference broth microdilution (BMD) according to

74 flow of bacterial and yeast ID and bacterial AST using the Accelerate Pheno system in the clinical mi

75 rom limitations of accuracy of culture-based AST in addition to an incomplete knowledge of the geneti

76 e results of the gold-standard culture-based AST measured over days.

77 The advantages of the proposed droplet-based AST, including rapid drug sensitivity response, morpholo

78 Yet current growth-based AST assays, such as broth microdilution(5), require seve

79 This imaging-based AST approach was used to determine the growth rates of f

80 Simple-to-use phenotype-based AST platforms can assist care-givers in timely prescript

81 ds (cholesterol, tryacylglicerol); (4) blood AST and ALT; (5) liver histology (histopathology, hemosi

82 Elevations of both AST and ALT are mostly below 5 times the upper reference

83 d the severity of IR injury as determined by AST and ALT levels, as well as immune cell infiltrates.

84 sistance pattern most frequently observed by AST devices was "cefoxitin resistance/oxacillin suscepti

85 s of liver injury indicators, represented by AST, correspond with COVID-19-related liver injury.

86 adsorption on MN200, much lower than that by AST (0.164) and slightly higher than that by RAST (0.069

87 by RAST (0.10) and much lower than those by AST (0.26) and FN model (0.38).

88 foundation to develop a rapid, point-of-care AST and strengthen global antibiotic stewardship.

89 Cefiderocol AST was performed on consecutive carbapenem-resistant En

90 tive approach to BMD methods for cefiderocol AST, with the exception of A. baumannii complex isolates

91 is considerable variability when cefiderocol ASTs are interpreted using CLSI, FDA, and EUCAST breakpo

92 stration (FDA) limitations on how commercial AST systems can be used for diagnostic testing, the abse

93 This viewpoint will highlight contemporary AST challenges faced by the clinical laboratory, and pro

94 nsplantation compared to untreated controls (AST 563.5 vs. 1204 U/L, P = 0.023).

95 Conventional AST methods require 16-24 h to assess sensitivity of the

96 ncluded history of vomiting, platelet count, AST level.

97 Results showed that levels of cT1, AST, GGT and fasting glucose were all good predictors of

98 the model identified the combination of cT1-AST-fasting glucose (cTAG) as far superior to any indivi

99 We describe the origins of current AST reference methodology, highlight the sources of AST

100 Current ASTs rely on time-consuming differentiation of resistanc

101 that our mobile-reader meets the FDA-defined AST criteria, with a well-turbidity detection accuracy o

102 inical events committee-adjudicated definite AST (occurring </=24 hours after percutaneous coronary i

103 An increased risk of definite AST was associated with shorter than with longer procedu

104 This digital AST (dAST) determined susceptibility of clinical isolate

105 laboratories for culture-based agar dilution AST with seven antibiotics and for whole-genome sequenci

106 nsing layer for reagent-free electrochemical AST.

107 79%), anemia (63%), alopecia (50%), elevated AST (50%), and constipation, nausea, and thrombocytopeni

108 = 2), thrombocytopenia (n = 2), and elevated AST/ALT (n = 1), were observed with schedule A; one dose

109 ose-limiting toxicity was observed (elevated AST/ALT) was observed with schedule B.

110 HCV patients, and populations with elevated AST/ALT.

111 into many small volumes during dPCR enabled AST results after short exposure times by 1) precise qua

112 view, we have discussed emerging engineering AST techniques with special emphasis on phenotypic AST.

113 els positively correlated with liver enzymes AST and ALT, and negatively correlated with white blood

114 ethods (DD) to broth microdilution (BMD) for AST of Gram-negative bacilli (GNB).

115 sification and achieved 100% concordance for AST.

116 mg/day plus rifaximin and placebo group (for AST -14 IU/L [-91 to 64; p=0.728] and for ALT -8 IU/L [-

117 to 43.9 h for ID and from 47.9 to 73.9 h for AST.

118 No probe was identified for AST levels.

119 tween the groups at the end of treatment for AST 130 IU/L [95% CI 54 to 205; p=0.0009] and for ALT 61

120 Here, we describe a label-free AST that can deliver results within an hour, using an ac

121 Detection of nucleic acids in genotypic AST can be rapid, but it has not been successful for bet

122 d the laboratory capacity for N. gonorrhoeae AST and associated genetic marker detection, expanding p

123 t-TLA TATs to organism IDs (18.5 to 16.9 h), AST results (41.8 to 40.8 h), and preliminary results fo

124 ein and albumin concentrations) and hepatic (AST) parameters returned to baseline.

125 High AST completely mediated the HBV infection-any cataract a

126 High AST significantly mediates the effects of HBV infections

127 r and any cataract were not mediated by high AST or ALT.

128 ct effects, not by mediation effects of high AST or ALT.

129 5%, and TBIL 4.3%) and peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, and TBIL 16.1%).

130 A significantly improved TAT to organism ID, AST report, and preliminary negative results.

131 ID/AST performance, the average times to results, and workf

132 Pheno system provides rapid and accurate ID/AST results for most of the organisms found routinely in

133 is easy to use, reduces hands on time for ID/AST of common blood pathogens, and enables clinically ac

134 cimen collection to reporting of organism ID/AST were evaluated and compared by specimen types and ch

135 ould check liver transaminases level, and if AST are above 100 IU/L, they should be aware of a possib

136 review, we discuss how and why PK-PD impacts AST and the way infectious diseases are being treated, w

137 variability, and propose ideas for improving AST predictive power.

138 flow is likely, and concomitant decreases in AST/ALT suggest an intrahepatic anti-inflammatory effect

139 ximin group showed a significant increase in AST and ALT compared with the placebo group (mean differ

140 Detection of these isolates in AST systems based on cefoxitin and/or oxacillin testing

141 ed no significant differences at 12 weeks in AST and ALT between the simvastatin 20 mg/day plus rifax

142 pathologic features in the livers, including AST, ALT, and a panel of cytokines and chemokines, were

143 a simple syringe injection step to initiate AST against all antibiotics.

144 ed proof of principle for various innovative AST methods, including both molecular-based and genome-b

145 ficient 0.887), align with the international AST standard (ISO 200776-1; 2006) and could be used for

146 increasingly unavailable clinical laboratory AST, although gonorrhea is on the rise with >550 000 US

147 (p<0.001), pretreatment transaminase levels (AST) (p=0.022), Child-Pugh subclassification (p=0.003),

148 and mitochondrial aspartate transaminase (m-AST).

149 es in levels of hepatobiliary injury markers AST, ALT, LDH, and gamma-GT after 6 hours of NMP.

150 ivity and 83% specificity and rapid (90 min) AST in 12 urine samples with 87.5% categorical agreement

151 nt and FDA regulatory approval of modernized AST to guide treatment.

152 ly, this platform builds on "pheno-molecular AST", a strategy that transforms nucleic acid amplificat

153 rhea is usually empirically treated, with no AST results available before treatment, thus contributin

154 Finally, the successful demonstration of AST on E. coli with a concentration of 10(3) CFU/mL is p

155 al enrichment, culture, and determination of AST.

156 T marrow exhibited only modest elevations of AST and ALT levels.

157 aled an overall increase in the frequency of AST errors in AD and MCI compared to the control group,

158 The "holy grail" of AST is a phenotype-based test that can be performed with

159 artate aminotransferase [AST]/upper limit of AST)/platelet.

160 ime was associated with an increased risk of AST in patients treated with bivalirudin but not patient

161 erence methodology, highlight the sources of AST variability, and propose ideas for improving AST pre

162 this Review, we discuss the current state of AST systems in the broadest technical, translational and

163 ll and bacterial suspension for the study of AST is also discussed.

164 point coincides with a European Committee on AST decision to remove previously established, differing

165 the clinical effect of procedure duration on AST when either bivalirudin or heparin plus glycoprotein

166 s (79%) experienced either grade >/=1 ALT or AST elevation during the study, and 13 subjects (54%) ex

167 erate and enable colorimetric readout in our AST.

168 Admission AST (69 vs. 49; P < 0.05), peak AST (364 vs. 77; P = 0.003), and peak ALT (220 vs. 52; P

169 tivariable logistic regression revealed peak AST (OR, 2.8; P = .0019), peak creatinine (OR, 7.3; P =

170 and/or PBP2a tests when requested to perform AST on atypical isolates of S. aureus.

171 e need for trained diagnosticians to perform AST, reduce the cost-barrier for routine testing, and as

172 in the United States to effectively perform ASTs is challenged by several factors.

173 ome a potentially useful tool for performing AST without trained personnel, laborious procedures, or

174 er-plate (MTP) reader, capable of performing AST without the need for trained diagnosticians.

175 e by providing rapid and accurate phenotypic AST data for virtually all available antibiotics in a si

176 assay for combined genotypic and phenotypic AST through RNA detection, GoPhAST-R, that classifies st

177 ange of antibiotics, conventional phenotypic AST requires overnight incubations, and new rapid phenot

178 f bacterial surfaces that enables phenotypic AST within 5 hours for non-fastidious bacteria.

179 amplification tests (NAATs) into phenotypic AST through quantitative detection of bacterial genomic

180 rd developing a critically needed phenotypic AST for Ng and additional global-health threats.

181 chniques with special emphasis on phenotypic AST.

182 his two-pronged approach provides phenotypic AST 24-36 h faster than standard workflows, with <4 h as

183 Rapid phenotypic AST for Ng is challenged by the pathogen's slow doubling

184 rnight incubations, and new rapid phenotypic AST platforms restrict the number of antibiotics tested

185 e approach for performing a rapid phenotypic AST that measures DNA accessibility to exogenous nucleas

186 excellent alternative to standard phenotypic AST with potential applications in clinical diagnostics

187 quantitative, and high-throughput phenotypic AST by measuring electrons transferred from the interior

188 d innovative approaches for rapid phenotypic ASTs for CREs are urgently needed.

189 minotransferase (ALT), alkaline phosphatase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL)

190 n Infectious Diseases Community of Practice (AST IDCOP) guidelines suggested to continue or reinstitu

191 had abnormal liver tests prehospitalization (AST 25.9%, ALT 38.0%, ALP 56.8%, and TBIL 44.4%).

192 er salivary concentrations of total protein, AST, ALT, and LDH than the CN group.

193 ed salivary concentrations of total protein, AST, ALT, and LDH, decreased salivary flow rate and a si

194 Rapid AST led to improved stewardship measures but did not imp

195 Rapid AST would transform the care of patients with infection

196 A rapid AST assay can assist clinicians in making an informed ch

197 huge potential in the development of a rapid AST device for applications in the clinical and pharmace

198 Here, we present a rapid AST platform using RNA signatures for Neisseria gonorrho

199 Hence, we developed a rapid AST using electroanalysis with a 15 min assay time, call

200 whom antibiotic change occurred after rapid AST result, rapid AST was associated with a trend in dec

201 opment and implementation of novel and rapid AST platforms in health-care settings.

202 Although conceptually new and rapid AST technologies have been described, including new phen

203 much attention has been on developing rapid AST techniques to avoid misuse of antibiotics and provid

204 ise, potentially providing a basis for rapid AST.

205 ic current is a promising approach for rapid AST.

206 may be required to clinically justify rapid AST implementation.

207 To date, many rapid AST methods have been developed, but few are able to be

208 We investigated the impact of rapid AST on clinical and antimicrobial stewardship outcomes i

209 l breakthrough that leads the field of rapid AST platform development.

210 hange occurred after rapid AST result, rapid AST was associated with a trend in decreased time to esc

211 urrent innovations and challenges with rapid AST, VISA/hVISA identification, and clinical bioinformat

212 Reference AST methods are based on bacterial growth in antibiotic

213 biotic treatment, enabling fast and reliable AST.

214 Continued, robust AST and genomic capacity can help inform national public

215 licated, because many do not grow on routine AST media, including Mueller-Hinton agar (MHA) and catio

216 an a model without fS-pIGFBP-1 or S-ALT or S-AST alone.

217 cantly increased hepatic steatosis and serum AST level as well as hepatic cellular NF-kappaB activati

218 alin A challenge, and display elevated serum AST and ALT levels, hyperactivation of NKT cells, and en

219 had a higher systolic blood pressure, serum AST, and ALT at 72 weeks, compared with baseline (p = 0.

220 and demonstrate agreement with gold-standard AST.

221 ation (ID) and antimicrobial susceptibility (AST) reports were calculated for 5,402 positive culture

222 We used the antisaccade task (AST) as a model task given the emerging consensus that i

223 Antibiotic susceptibility test (AST) is essential in clinical diagnosis of serious bacte

224 me-consuming antibiotic susceptibility test (AST) methods limit physicians in selecting proper antibi

225 ent-level antimicrobial susceptibility test (AST) results for Enterococcus spp., Escherichia coli, St

226 ents) show that active surveillance testing (AST) followed by contact precautions for positive patien

227 tee on Antimicrobial Susceptibility Testing (AST SC) is a volunteer-led, multidisciplinary consensus

228 on and antimicrobial susceptibility testing (AST) at the single-cell level.

229 nce of antimicrobial susceptibility testing (AST) by the clinical laboratory is paramount to combatin

230 outine antimicrobial susceptibility testing (AST) can prevent deaths due to bacteria and reduce the s

231 t, AZI antimicrobial susceptibility testing (AST) cannot be interpreted using recognized standards.

232 tional antimicrobial susceptibility testing (AST) confirmed a high correlation between genotypic and

233 Rapid antibiotic susceptibility testing (AST) for Neisseria gonorrhoeae (Ng) is critically needed

234 rapid antimicrobial susceptibility testing (AST) in Gram-negative rod (GNR) bacteremia is compelling

235 accurate antibiotic susceptibility testing (AST) is a critical need in addressing escalating antibio

236 Antimicrobial susceptibility testing (AST) is a fundamental mission of the clinical microbiolo

237 Antimicrobial susceptibility testing (AST) is an essential diagnostic procedure to determine t

238 Rapid antibiotic susceptibility testing (AST) is critical in determining bacterial resistance or

239 liable antimicrobial susceptibility testing (AST) is developed.

240 tional antimicrobial susceptibility testing (AST) is intrinsically limited by observation of cell col

241 simple antimicrobial susceptibility testing (AST) is urgently required to guide effective antibiotic

242 s) for antimicrobial susceptibility testing (AST) methods and results interpretation in the United St

243 ia and antimicrobial susceptibility testing (AST) methods specific to the CoNS group were used to eva

244 vitro antimicrobial susceptibility testing (AST) of aztreonam-avibactam is not commercially availabl

245 reliable antibiotic susceptibility testing (AST) of bacterial pathogens is essential.

246 Antimicrobial susceptibility testing (AST) of cefiderocol poses challenges because of its uniq

247 D) and antimicrobial susceptibility testing (AST) of respiratory pathogens are critical to the manage

248 Antimicrobial susceptibility testing (AST) of these isolates is complicated, because many do n

249 tools and antibiotic susceptibility testing (AST) prediction using ARESdb compared to matrix-assisted

250 Antimicrobial susceptibility testing (AST) provides valuable information on the efficacy of an

251 -standard antibiotic susceptibility testing (AST) remains unacceptably slow (1-2 d), and innovative a

252 D) and antimicrobial susceptibility testing (AST) results for the most commonly identified organisms

253 D) and antimicrobial susceptibility testing (AST) results within 8h of blood culture growth.

254 e CLSI antimicrobial susceptibility testing (AST) subcommittee endorsed the CBDE and CAT-10 methods f

255 omated antimicrobial susceptibility testing (AST) systems and five selective chromogenic agar plates.

256 Antimicrobial susceptibility testing (AST) systems are the collective set of diagnostic proces

257 Antimicrobial susceptibility testing (AST) technologies help to accelerate the initiation of t

258 rapid antimicrobial susceptibility testing (AST) technologies that will enable evidence-based treatm

259 faster antimicrobial susceptibility testing (AST) to guide antibiotic treatment.

260 Rapid antimicrobial susceptibility testing (AST) would decrease misuse and overuse of antibiotics.

261 curate antimicrobial susceptibility testing (AST) would rule out standard treatment with vancomycin.

262 ID) or antimicrobial susceptibility testing (AST), resulting in delayed therapeutic decisions at the

263 otypic antimicrobial susceptibility testing (AST), with promising results.

264 -based antimicrobial susceptibility testing (AST).

265 on and antimicrobial susceptibility testing (AST).

266 and fast antimicrobial susceptibility tests (ASTs) that allow informed prescribing of antibiotics.

267 The AST systems showed false-negative results with varying n

268 ept of frailty among transplant centers, the AST and ASTS supported the efforts of our working group

269 on surrounding this important topic from the AST Transplantation Research forum, is provided.

270 There was an earlier peak in the AST distribution of the saccadic reaction times for the

271 the previously mentioned risk factors in the AST IDCOP guidelines.

272 e variables in addition to the timing of the AST result contribute to clinical outcome and that furth

273 Thereby, speed and sensitivity of the AST results are crucial for improving patient care.

274 functions, and operational processes of the AST SC.

275 ce in transplant recipients, the goal of the AST-sponsored conference and the consensus documents pro

276 acillin-tazobactam and imipenem found on the AST-GN69 card, with no very major or major errors noted

277 n of antibiotic susceptibility, reducing the AST time to 1-2 days.

278 emerged as a topic of great interest to the AST community.

279 t (START) trial for liver fibrosis using the AST to Platelet Ratio Index (APRI) and Fibrosis-4 Index

280 te adsorption, the adsorbed solution theory (AST) and real adsorbed solution theory (RAST) either fre

281 average time to antistaphylococcal therapy (AST) in MSSA infection declined during the study (3.7 da

282 , increased rates of acute stent thrombosis (AST) have been noted when bivalirudin is discontinued at

283 he past 30 years, only a few high-throughput AST methods have been developed and widely implemented.

284 Here, we introduce a novel approach to AST based on signal amplification of bacterial surfaces

285 omic data with aspartate amino transaminase (AST), a hepatic leakage enzyme to assess organ damage, a

286 profoundly elevated aspartate transaminase (AST) and alanine transaminase (ALT) levels, indicative o

287 transaminase (ALT), aspartate transaminase (AST), and liver fat content.

288 of the American Society of Transplantation (AST) conference on frailty.

289 ns, the American Society of Transplantation (AST) facilitated a consensus workshop to comprehensively

290 17, the American Society of Transplantation (AST) launched the Outstanding Questions in Transplantati

291 vations 1-2x the upper limit of normal (ULN; AST 63.7%, ALT 63.5%, ALP 80.0%, and TBIL 75.7%).

292 Unfortunately, AST for vancomycin is relatively slow and standard metho

293 reated with broad spectrum antibiotics until AST results become available, which has contributed to t

294 In clinical laboratories, most widely used AST methods are disk diffusion, gradient diffusion, brot

295 We argue that standardization of WGS-AST by challenge with consistently phenotyped strain set

296 g for antibiotic susceptibility testing (WGS-AST) is now a powerful alternative.

297 ical laboratory will be asked to select what AST method(s) to use and to provide data monitoring outc

298 sed models were then built and compared with AST and RAST, based on which a new modeling strategy cou

299 Fibrosis-4 (FIB-4) was calculated as (age x AST)/(platelet x radical alanine aminotransferase [ALT])

300 Yet AST is critical for detecting and monitoring AR-Ng.